Surveying Tomorrow’s BioPharma Landscape.pdfVIP

Surveying Tomorrow’s BioPharma Landscape The NASDAQ Biotech Index Up Close Welcome to the EvaluatePharma? Survey of Tomorrow’s BioPharma Landscape In this exclusive report, EvaluatePharma introduces a snapshot of the companies behind the widely-cited NASDAQ Biotechnology Index (NBI). This aggregate analysis of leading, publicly-traded biotech, pharma and tools companies that make up the NBI offers readers a window onto tomorrow’s BioPharma landscape of products and pipelines. It also provides insight into this dynamic sector, by analyzing the changing number, rankings, composition and therapeutic area foci of the NBI’s constituent companies. A pdf version of this report can be found at /NBI2012. EvaluatePharma has developed a reliable and consistent methodology to forecast product sales based on equity research analysts’ projections. The key steps carried out for product sales forecasts by EvaluatePharma Analysts are as follows: ? Review company presentations to analysts, news flow and SEC filings, for key financial and operating drivers ? Collate forecasts of product sales, segment sales, costs and earnings per share from equity research analyst reports ? Create a consensus forecast based on the arithmetic average of most recent forecasts ? Build detailed group sales forecasts from consensus product and segment sales forecasts Jonathan de Pass CEO, EvaluatePharma LTD June 2012 2C o p yr ig h t ? 2 01 2 Ev al u at eP h ar m a Lt d . A ll ri g h ts r es er ve d . The NASDAQ Biotech Index is cited all around the world but rarely do we see a detailed aggregate analysis of these leading, publicly traded biotechnology companies. This overview provides insight into the breadth and scope of today’s biotech products and where this dynamic sector is heading. Table of Contents 4 Executive Summary 5 NBI Companies and Products 6 NBI Marketed Drugs: CNS, Anti-Infectives Dominate 8 NBI Pipeline Drugs: Driven by Biologics, Oncology 12 NBI Dia